| Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition LR Ferguson, H Chen, AR Collins, M Connell, G Damia, S Dasgupta, ... Seminars in cancer biology 35, S5-S24, 2015 | 389 | 2015 |
| Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact C Foroni, M Broggini, D Generali, G Damia Cancer treatment reviews 38 (6), 689-697, 2012 | 375 | 2012 |
| Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action E Erba, D Bergamaschi, L Bassano, G Damia, S Ronzoni, GT Faircloth, ... European Journal of Cancer 37 (1), 97-105, 2001 | 350 | 2001 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 324 | 2015 |
| Platinum resistance in ovarian cancer: role of DNA repair G Damia, M Broggini Cancers 11 (1), 119, 2019 | 272 | 2019 |
| Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways G Damia, S Silvestri, L Carrassa, L Filiberti, GT Faircloth, G Liberi, ... International journal of cancer 92 (4), 583-588, 2001 | 206 | 2001 |
| E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models E Bello, G Colella, V Scarlato, P Oliva, A Berndt, G Valbusa, SC Serra, ... Cancer research 71 (4), 1396-1405, 2011 | 178 | 2011 |
| DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy L Carrassa, G Damia Cancer treatment reviews 60, 139-151, 2017 | 175 | 2017 |
| Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti‐cancer agents G Damia, L Imperatori, M Stefanini, M D'Incalci International journal of cancer 66 (6), 779-783, 1996 | 152 | 1996 |
| Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations F Ricci, F Bizzaro, M Cesca, F Guffanti, M Ganzinelli, A Decio, C Ghilardi, ... Cancer research 74 (23), 6980-6990, 2014 | 146 | 2014 |
| Cisplatinum and taxol induce different patterns of p53 phosphorylation G Damia, L Filiberti, F Vikhanskaya, L Carrassa, Y Taya, M Dincalci, ... Neoplasia 3 (1), 10-16, 2001 | 138 | 2001 |
| Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo L Carrassa, R Chilà, M Lupi, F Ricci, C Celenza, M Mazzoletti, M Broggini, ... Cell Cycle 11 (13), 2507-2517, 2012 | 135 | 2012 |
| Role of homologous recombination in trabectedin-induced DNA damage M Tavecchio, M Simone, E Erba, I Chiolo, G Liberi, M Foiani, M D’Incalci, ... European Journal of Cancer 44 (4), 609-618, 2008 | 132 | 2008 |
| Targeting DNA repair as a promising approach in cancer therapy G Damia, M D’Incalci European Journal of Cancer 43 (12), 1791-1801, 2007 | 127 | 2007 |
| Contemporary pre-clinical development of anticancer agents–what are the optimal preclinical models? G Damia, M D’Incalci European Journal of Cancer 45 (16), 2768-2781, 2009 | 119 | 2009 |
| Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing, or not, p53 L Carrassa, M Broggini, E Erba, G Damia Cell Cycle 3 (9), 1175-1179, 2004 | 111 | 2004 |
| A work in progress: the clinical development of histone deacetylase inhibitor S Marsoni, G Damia, G Camboni Epigenetics 3 (3), 164-171, 2008 | 107 | 2008 |
| Unleashing Chk1 in cancer therapy L Carrassa, G Damia Cell cycle 10 (13), 2121-2128, 2011 | 97 | 2011 |
| International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the … A Berruti, D Generali, M Kaufmann, L Puztai, G Curigliano, M Aglietta, ... Journal of the National Cancer Institute Monographs 2011 (43), 147-151, 2011 | 95 | 2011 |
| Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity M Simone, E Erba, G Damia, F Vikhanskaya, AM Di Francesco, R Riccardi, ... European Journal of Cancer 41 (15), 2366-2377, 2005 | 94 | 2005 |
broggini massimoIstituto Mario NegriVerified email at marionegri.it
